Several studies have shown the usefulness of contrast-enhanced MR angiography (CE-MRA) for imaging the supraortic vessels, and, as a consequence, it has rapidly become a routine imaging modality. The main advantage over unenhanced techniques is the possibility to acquire larger volumes, allowing demonstration of the carotid artery from its origin to the intracranial portion. Most published studies on CE-MRA of the carotid arteries have been performed with standard Gd-based chelates whose T1 relaxivity values are similar. Recently new gadolinium chelates such as gadobenate dimeglumine (Gd-BOP-TA, MultiHance; Bracco Imaging, Milan, Italy) have been developed which have markedly higher intravascular T1 relaxivity values. When administered at an equivalent dose to that of a standard agent, these newer contrast agents produce significantly greater intravascular signal enhancement. The availability of an appropriate high-relaxivity contrast agent might also help to overcome some of the intrinsic technical problems (e. g. those related to flow) that affect time-of-flight (TOF) and phase contrast (PC) MR angiography of the intracranial vasculature. To avoid the problem of superimposition of veins, ultrafast gradient echo MRA techniques with very short TR and TE have been developed. Although the precise sequence parameters vary between manufacturers, they are basically similar. The choice between performing a time-resolved or high spatial resolution CE-MRA examination depends upon the precise clinical application. The most common applications include the study of cerebral aneurysms, arteriovenous malformations, dural arteriovenous fistulas and dural venous diseases.